# Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study

> **NCT07495384** · NA · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer
- Platinum Resistance

## Interventions

- **DRUG:** CapsuleX

## Key facts

- **NCT ID:** NCT07495384
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2029-11-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07495384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07495384, "Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07495384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*